PTCT Quote, Financials, Valuation and Earnings

Palatin Technologies has a net margin of 7.53% compared to PTC Therapeutics, Inc.'s net margin of --. PTC Therapeutics, Inc.'s return on equity of -- beat Palatin Technologies's return on equity of --.

PTC Therapeutics, Inc. has a consensus price target of $81.86, signalling upside risk potential of 5.15%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 7338.9%. Given that Palatin Technologies has higher upside potential than PTC Therapeutics, Inc., analysts believe Palatin Technologies is more attractive than PTC Therapeutics, Inc..

PTC Therapeutics, Inc. has a beta of 0.470, which suggesting that the stock is 52.999% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.103%.

PTC Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PTC Therapeutics, Inc. pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

PTC Therapeutics, Inc. quarterly revenues are $211M, which are larger than Palatin Technologies quarterly revenues of --. PTC Therapeutics, Inc.'s net income of $15.9M is higher than Palatin Technologies's net income of --. Notably, PTC Therapeutics, Inc.'s price-to-earnings ratio is 9.10x while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PTC Therapeutics, Inc. is 3.60x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Pyxis Oncology, Inc. has a net margin of 7.53% compared to PTC Therapeutics, Inc.'s net margin of -650.85%. PTC Therapeutics, Inc.'s return on equity of -- beat Pyxis Oncology, Inc.'s return on equity of -90.91%.

PTC Therapeutics, Inc. has a consensus price target of $81.86, signalling upside risk potential of 5.15%. On the other hand Pyxis Oncology, Inc. has an analysts' consensus of $7.68 which suggests that it could grow by 77.66%. Given that Pyxis Oncology, Inc. has higher upside potential than PTC Therapeutics, Inc., analysts believe Pyxis Oncology, Inc. is more attractive than PTC Therapeutics, Inc..

PTC Therapeutics, Inc. has a beta of 0.470, which suggesting that the stock is 52.999% less volatile than S&P 500. In comparison Pyxis Oncology, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

PTC Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pyxis Oncology, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PTC Therapeutics, Inc. pays -- of its earnings as a dividend. Pyxis Oncology, Inc. pays out -- of its earnings as a dividend.

PTC Therapeutics, Inc. quarterly revenues are $211M, which are larger than Pyxis Oncology, Inc. quarterly revenues of --. PTC Therapeutics, Inc.'s net income of $15.9M is higher than Pyxis Oncology, Inc.'s net income of -$22M. Notably, PTC Therapeutics, Inc.'s price-to-earnings ratio is 9.10x while Pyxis Oncology, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PTC Therapeutics, Inc. is 3.60x versus 93.87x for Pyxis Oncology, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Rigel Pharmaceuticals, Inc. has a net margin of 7.53% compared to PTC Therapeutics, Inc.'s net margin of 40.17%. PTC Therapeutics, Inc.'s return on equity of -- beat Rigel Pharmaceuticals, Inc.'s return on equity of 273.99%.

PTC Therapeutics, Inc. has a consensus price target of $81.86, signalling upside risk potential of 5.15%. On the other hand Rigel Pharmaceuticals, Inc. has an analysts' consensus of $49.60 which suggests that it could grow by 4.69%. Given that PTC Therapeutics, Inc. has higher upside potential than Rigel Pharmaceuticals, Inc., analysts believe PTC Therapeutics, Inc. is more attractive than Rigel Pharmaceuticals, Inc..

PTC Therapeutics, Inc. has a beta of 0.470, which suggesting that the stock is 52.999% less volatile than S&P 500. In comparison Rigel Pharmaceuticals, Inc. has a beta of 1.110, suggesting its more volatile than the S&P 500 by 11.026%.

PTC Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Rigel Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PTC Therapeutics, Inc. pays -- of its earnings as a dividend. Rigel Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

PTC Therapeutics, Inc. quarterly revenues are $211M, which are larger than Rigel Pharmaceuticals, Inc. quarterly revenues of $69.5M. PTC Therapeutics, Inc.'s net income of $15.9M is lower than Rigel Pharmaceuticals, Inc.'s net income of $27.9M. Notably, PTC Therapeutics, Inc.'s price-to-earnings ratio is 9.10x while Rigel Pharmaceuticals, Inc.'s PE ratio is 7.68x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PTC Therapeutics, Inc. is 3.60x versus 3.09x for Rigel Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics, Inc. has a net margin of 7.53% compared to PTC Therapeutics, Inc.'s net margin of --. PTC Therapeutics, Inc.'s return on equity of -- beat Theriva Biologics, Inc.'s return on equity of -171.04%.

PTC Therapeutics, Inc. has a consensus price target of $81.86, signalling upside risk potential of 5.15%. On the other hand Theriva Biologics, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 3398.25%. Given that Theriva Biologics, Inc. has higher upside potential than PTC Therapeutics, Inc., analysts believe Theriva Biologics, Inc. is more attractive than PTC Therapeutics, Inc..

PTC Therapeutics, Inc. has a beta of 0.470, which suggesting that the stock is 52.999% less volatile than S&P 500. In comparison Theriva Biologics, Inc. has a beta of 0.342, suggesting its less volatile than the S&P 500 by 65.818%.

PTC Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PTC Therapeutics, Inc. pays -- of its earnings as a dividend. Theriva Biologics, Inc. pays out -- of its earnings as a dividend.

PTC Therapeutics, Inc. quarterly revenues are $211M, which are larger than Theriva Biologics, Inc. quarterly revenues of --. PTC Therapeutics, Inc.'s net income of $15.9M is higher than Theriva Biologics, Inc.'s net income of -$4.4M. Notably, PTC Therapeutics, Inc.'s price-to-earnings ratio is 9.10x while Theriva Biologics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PTC Therapeutics, Inc. is 3.60x versus 0.33x for Theriva Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.